L.J.Davis, PharmD

Professor of Practice, Clinical and Regulatory Affairs

[Eric Topol @EricTopol]

There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines
https://t.co/e04jqJMPw0

[L.J.Davis, PharmD @MedicineDigest]

@HawkeyeRoad And a study in JAMA including 22.7 million vaxed individuals and 5.9 million unvaxed individuals; vaccinated individuals had a 74% lower risk of death from severe COVID-19 and no increased risk of all-cause mortality over a median follow-up of 45 months.

https://t.co/RGSbQAeUHs

[L.J.Davis, PharmD @MedicineDigest]

@kevinmd Perhaps there is another root cause at work here. Why did she never see her primary care physician and yet was finally able to be seen by a specialist? Even in a large managed care org a patient should be able to secure a primary care appointment well within 4 months.

[L.J.Davis, PharmD @MedicineDigest]

@MichelleMaxwell Some good information from the Bay Area Lyme Foundation. https://t.co/KNrqUAc0YJ

[L.J.Davis, PharmD @MedicineDigest]

@drobiy12 @DocPriyamMD Acetaminophen (paracetamol, Tylenol) is safe at therapeutic doses but is a leading cause of acute liver failure when overdosed. Please DO NOT take 12 gm/d. Max daily dose should be 3-4 gm/d at most from all sources (including acetaminophen found in many combination products).

[L.J.Davis, PharmD @MedicineDigest]

@wunderdarp @DrNeilStone This study does not appear to have a natural history comparison with an unvaxed cohort. Also numerous peer-reviewed studies, & analyses suggest delays in cancer Dx during the COVID pandemic due to factors like reduced access, resource diversion, lockdowns, fear of infection etc.

[L.J.Davis, PharmD @MedicineDigest]

@MaryBowdenMD @US_FDA JAMA cohort study - 22.7 million vaccinated individuals and 5.9 million unvaccinated individuals; vaccinated individuals had a 74% lower risk of death from severe COVID-19 and no increased risk of all-cause mortality over a median follow-up of 45 months. https://t.co/27rVSih6X6

[L.J.Davis, PharmD @MedicineDigest]

@WEschenbach @drterrysimpson There is a major difference however. There are two FDA-approved monoclonal antibody treatments and a vaccine specifically for the Zaire Ebola virus. No FDA approved treatments or vaccine are available for the more rare Bundibugyo virus species.

[L.J.Davis, PharmD @MedicineDigest]

@SenRonJohnson This meta analysis in JAMA and multiple other systematic analyses and individual studies don't support your ascertion. https://t.co/mSlxJfmCrc

[L.J.Davis, PharmD @MedicineDigest]

@jsm2334 @stkirsch JAMA - 22.7 mil vaxed vs 5.9 mil unvaxed: Vaxed individuals had a 74% lower risk of death from severe COVID-19 vs unvaxed and a 25% lower risk of all-cause mortality. No increased risk of 4-year all-cause mortality was onserved for vaxed individuals.

[L.J.Davis, PharmD @MedicineDigest]

@jsm2334 @stkirsch JAMA - 22.7 mil vaxed vs 5.9 mil unvaxed: Vaxed individuals had a 74% lower risk of death from severe COVID-19 vs unvaxed and a 25% lower risk of all-cause mortality. No increased risk of 4-year all-cause mortality was onserved for vaxed individuals.

[L.J.Davis, PharmD @MedicineDigest]

@jsolomonReports This outbreak is different. The outbreak is caused by the Bundibugyo virus which is a rarer ebola species and does not yet have an approved vaccine or treatment. There are some agents in development that could potentially be deployed in the context of a clinical trial, however.

[L.J.Davis, PharmD @MedicineDigest]

@RaianyRomanni There still remains a major hurdle, lack of an FDA approval pathway for aging or healthy lifespan extension and time required to establish meaningful effects in human studies.

[Eric Feigl-Ding @DrEricDing]

📉25% LOWER ALL-CAUSE MORTALITY! Wowzers—one of the largest long-term safety studies ever undertaken—offers the clearest answer yet: “Among 28 million French adults aged 18–59, those who received an mRNA-based COVID-19 vaccine were less likely to die in the subsequent four years than those who remained unvaccinated, corresponding to a 25% lower risk of death from all causes.”—and works even better among young adults—⬇️35% lower risk for ages 18-29!

Links in thread 🧵 below👇

[L.J.Davis, PharmD @MedicineDigest]

Chronic traumatic encephalopathy (CTE): A degenerative brain disorder in some people who have had repeated head impacts over time.

[Candy @RRgirl1313]

@NIH @NIHDirector_Jay What is CTE??

[L.J.Davis, PharmD @MedicineDigest]

Lancet meta analysis from 68 studies. Effectiveness Findings: Primary Series Vax (Against Any SARS-CoV-2 Strain) - Against hospitalizations: 92% at baseline, waning to 79% by 224–251 days. Against mortality: 91% at baseline, waning to 86% by 168–195 days.
https://t.co/PhjMXJuJG8

[Harry Fisher @harryfisherEMTP]

Based on what I experienced as a paramedic. They gave the Covid shots to destroy a portion of the population and remove people from our military that were smart enough to refuse.

This was an attack. It still is an ongoing attack. And those alive that push for the covid shot, are mentally unstable.

God bless

[L.J.Davis, PharmD @MedicineDigest]

Lancet meta analysis from 68 studies. Effectiveness Findings: Primary Series Vax (Against Any SARS-CoV-2 Strain) - Against hospitalizations: 92% at baseline, waning to 79% by 224–251 days. Against mortality: 91% at baseline, waning to 86% by 168–195 days.
https://t.co/PhjMXJuJG8

[Mary Talley Bowden MD @MaryBowdenMD]

No they don’t. That’s why we broke free from you.

[L.J.Davis, PharmD @MedicineDigest]

@MaryBowdenMD @drterrysimpson Using Grok to review SEER cancer database: Pre-pandemic baseline: median age at dx consistently around 62–63 yrs in recent pre-2020 periods. Post-pandemic (2021 onward): The median remains 63 yrs in the latest available combined periods. Some temporary dx delays during pandemic.

[L.J.Davis, PharmD @MedicineDigest]

@rand_longevity @AInnovator_ Could be escape velocity but even if we had 10 drugs with completed IND enabling studies with biologic plausibility for life span extension, would take another 10 - 15 yrs to produce 1 approved tx. Further, the FDA doesn't yet recognize aging as a disease eligible for approval.

[L.J.Davis, PharmD @MedicineDigest]

@metabolic_print Not necessarily...you might want to check the data:
https://t.co/XtWkVLAzJN

[Eric Topol @EricTopol]

People age 70+ should not be taking aspirin at any dose for prevention. Results of randomized trials show higher risk of all-cause mortality, major bleeding events and deaths from cancer. p 153, SUPER AGERS book

[L.J.Davis, PharmD @MedicineDigest]

@ATinyGreenCell @srikosuri @MartinBJensen So you expect government (tax payers) to spend ~$1.5 B over 10-15 yrs with a 10% chance of success to develop one new drug? Further, cover all post market costs, safety surveillance, HCP education, manufacturing & QC, quality complaint reporting, supply chain, audit readiness etc